Charles Schwab’s GenMark Diagnostics, Inc GNMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-472,987
| Closed | -$11.3M | – | 3628 |
|
|
2021
Q1 | $11.3M | Sell |
472,987
-95,938
| -17% | -$1.78M | ﹤0.01% | 1889 |
|
|
2020
Q4 | $8.31M | Buy |
568,925
+13,979
| +3% | +$185K | ﹤0.01% | 1967 |
|
|
2020
Q3 | $7.88M | Buy |
554,946
+65,114
| +13% | +$995K | ﹤0.01% | 1841 |
|
|
2020
Q2 | $7.21M | Buy |
489,832
+160,295
| +49% | +$1.63M | ﹤0.01% | 1842 |
|
|
2020
Q1 | $1.36M | Buy |
329,537
+4,759
| +1% | +$22.3K | ﹤0.01% | 2413 |
|
|
2019
Q4 | $1.56M | Buy |
324,778
+8,334
| +3% | +$46K | ﹤0.01% | 2481 |
|
|
2019
Q3 | $1.92M | Sell |
316,444
-9,231
| -3% | -$57.6K | ﹤0.01% | 2390 |
|
|
2019
Q2 | $2.11M | Buy |
325,675
+16,551
| +5% | +$117K | ﹤0.01% | 2355 |
|
|
2019
Q1 | $2.19M | Buy |
309,124
+13,738
| +5% | +$90.5K | ﹤0.01% | 2339 |
|
|
2018
Q4 | $1.44M | Sell |
295,386
-3,756
| -1% | -$19.6K | ﹤0.01% | 2429 |
|
|
2018
Q3 | $2.2M | Buy |
299,142
+24,292
| +9% | +$178K | ﹤0.01% | 2402 |
|
|
2018
Q2 | $1.75M | Buy |
274,850
+42,122
| +18% | +$278K | ﹤0.01% | 2413 |
|
|
2018
Q1 | $1.27M | Buy |
232,728
+6,786
| +3% | +$33.7K | ﹤0.01% | 2452 |
|
|
2017
Q4 | $943K | Buy |
225,942
+9,048
| +4% | +$54.4K | ﹤0.01% | 2524 |
|
|
2017
Q3 | $2.09M | Sell |
216,894
-9,430
| -4% | -$98K | ﹤0.01% | 2273 |
|
|
2017
Q2 | $2.68M | Sell |
226,324
-9,730
| -4% | -$124K | ﹤0.01% | 2118 |
|
|
2017
Q1 | $3.03M | Buy |
236,054
+56,876
| +32% | +$685K | ﹤0.01% | 2019 |
|
|
2016
Q4 | $2.19M | Buy |
179,178
+22,059
| +14% | +$262K | ﹤0.01% | 2146 |
|
|
2016
Q3 | $1.85M | Buy |
157,119
+7,974
| +5% | +$77K | ﹤0.01% | 2166 |
|
|
2016
Q2 | $1.3M | Buy |
149,145
+3,426
| +2% | +$23.5K | ﹤0.01% | 2255 |
|
|
2016
Q1 | $768K | Buy |
145,719
+3,695
| +3% | +$20.6K | ﹤0.01% | 2427 |
|
|
2015
Q4 | $1.1M | Buy |
142,024
+5,481
| +4% | +$42.1K | ﹤0.01% | 2350 |
|
|
2015
Q3 | $1.07M | Buy |
136,543
+31,761
| +30% | +$294K | ﹤0.01% | 2361 |
|
|
2015
Q2 | $950K | Sell |
104,782
-26,996
| -20% | -$272K | ﹤0.01% | 2437 |
|
|
2015
Q1 | $1.71M | Buy |
131,778
+6,837
| +5% | +$89.4K | ﹤0.01% | 2138 |
|
|
2014
Q4 | $1.7M | Buy |
124,941
+31,037
| +33% | +$347K | ﹤0.01% | 2109 |
|
|
2014
Q3 | $843K | Buy |
93,904
+2,030
| +2% | +$21.8K | ﹤0.01% | 2378 |
|
|
2014
Q2 | $1.24M | Buy |
91,874
+9,260
| +11% | +$96.6K | ﹤0.01% | 2227 |
|
|
2014
Q1 | $822K | Buy |
82,614
+2,400
| +3% | +$29.8K | ﹤0.01% | 2382 |
|
|
2013
Q4 | $1.07M | Buy |
80,214
+2,880
| +4% | +$35K | ﹤0.01% | 2237 |
|
|
2013
Q3 | $947K | Buy |
77,334
+18,810
| +32% | +$202K | ﹤0.01% | 2235 |
|
|
2013
Q2 | $617K | Buy |
+58,524
| New | +$807K | ﹤0.01% | 2418 |
|
Charles Schwab's GNMK Position: Q2 2021 in Review
Charles Schwab sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 472,987 shares — an estimated $11.3M sold.
Charles Schwab first reported a position in GNMK in Q2 2013 and held it in 32 quarters. The position peaked at $11.3M in Q1 2021. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.
- Charles Schwab reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
- Charles Schwab sold 472,987 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $11.3M.
- Charles Schwab first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 32 quarters.
- Charles Schwab's GenMark Diagnostics, Inc position peaked at $11.3M in Q1 2021.
- 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.
Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.